论文部分内容阅读
目的探讨三维适形放射治疗联合多西紫杉醇和顺铂(TP方案)化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法选取2010年3月至2013年3月间收治的60例晚期NSCLC患者,随机分为对照组和观察组,每组30例。对照组患者给予单纯TP方案化疗,观察组患者给予三维适形放射治疗联合TP方案化疗,观察两组患者的临床疗效、1年、2年生存率和不良反应发生情况。结果对照组患者治疗总有效率为56.7%,观察组患者为83.3%。对照组患者的1年和2年生存率分别为53.3%和40.0%,生存时间为(10.9±1.7)个月;观察组患者的1年和2年生存率分别为80.0%和56.7%,生存时间为(18.6±2.1)个月。两组患者早期放射性反应主要为Ⅰ~Ⅱ级放射性食管炎和骨髓抑制,晚期放射性反应主要为Ⅰ~Ⅱ级放射性肺炎。结论三维适形放射治疗联合TP方案化疗治疗晚期NSCLC,可有效提高患者的近期疗效,延长患者的生存时间,不良反应可以耐受,但有增加的趋势。
Objective To investigate the clinical efficacy and safety of three-dimensional conformal radiotherapy combined with docetaxel and cisplatin (TP regimen) chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Sixty patients with advanced NSCLC who were admitted between March 2010 and March 2013 were randomly divided into control group and observation group, 30 cases in each group. Patients in the control group were treated with simple TP regimen. Patients in the observation group were given three-dimensional conformal radiotherapy combined with TP regimen. The clinical efficacy, 1 year, 2 year survival rate and adverse reactions were observed in both groups. Results The total effective rate was 56.7% in the control group and 83.3% in the observation group. The 1-year and 2-year survival rates in the control group were 53.3% and 40.0%, respectively, and the survival time was (10.9 ± 1.7) months. The 1-year and 2-year survival rates in the observation group were 80.0% and 56.7% The time was (18.6 ± 2.1) months. The two groups of patients with early radioactive mainly Ⅰ ~ Ⅱ radio esophagitis and myelosuppression, advanced radioactive mainly Ⅰ ~ Ⅱ level of radiation pneumonitis. Conclusion Three-dimensional conformal radiotherapy combined with TP regimen in the treatment of advanced NSCLC can effectively improve the short-term efficacy of patients, prolong the survival time of patients, adverse reactions can be tolerated, but there is an increasing trend.